July 24, 2016 12:36 AM ET


Company Overview of Second Genome, Inc.

Company Overview

Second Genome, Inc., a biopharmaceutical company, focuses on the microbiome drug discovery and development. Its lead candidate SGM-1019 is a small molecule inhibitor of a key microbiome-mediated target to address inflammation and pain in inflammatory bowel disease (IBD). The company is also involved in various preclinical programs under development for a range of chronic indications. Second Genome, Inc. has strategic partnerships with Janssen Biotech and Mayo Clinic. It was formerly known as PhyloTech, Inc. and changed its name to Second Genome, Inc. in January 2011. The company was founded in 2009 and is based in South San Francisco, California.

341 Allerton Avenue

South San Francisco, CA 94080

United States

Founded in 2009



Key Executives for Second Genome, Inc.

Chief Executive Officer, President and Director
Age: 57
Co-Founder and Chairman of the Board
Age: 59
Co-Founder and Senior Director of Bioinformatics
Chief Business Officer
Age: 52
Compensation as of Fiscal Year 2016.

Second Genome, Inc. Key Developments

Second Genome, Inc. Appoints Glenn Nedwin as Chief Executive Officer, President and Member of the Board and Jill Carroll to the Board of Directors

Second Genome, Inc. announced the appointment of Glenn Nedwin, Ph.D., as chief executive officer, president and member of the company's board of directors. Dr. Nedwin joins Second Genome as the company accelerates the translation of its microbiome discoveries into a pipeline of clinical opportunities. The company also announced Jill Carroll of SR One has joined the company's board of directors. Most recently, Dr. Nedwin was chief executive officer of Taxon Biosciences, Inc.

Second Genome, Inc. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 08:45 AM

Second Genome, Inc. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 08:45 AM. Venue: Parc 55 Hotel, San Francisco, California, United States.

Second Genome, Inc. and Evotec AG to Collaborate in Microbiome Discovery and Development

Evotec AG and Second Genome, Inc. announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome's unique approach to identify and modulate microbiome-mediated pathways will be further enhanced by the use and the results of Evotec's integrated drug discovery platform. As part of the collaboration, Second Genome and Evotec will work together to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec's technology platform, chemical libraries and other pre-clinical capabilities. The agreement between Evotec and Second Genome triggers an undisclosed upfront payment. Evotec is also eligible for pre-clinical, clinical and regulatory milestones as well as royalty payments related to commercialisation.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Private Placement
April 20, 2016

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Second Genome, Inc., please visit www.secondgenome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.